Cargando…

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer

Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Min, Jia, Qingqing, Wang, Xiaolin, Sun, Changjiang, Yang, Jianqi, Chen, Yanliang, Li, Ying, Min, Lingfeng, Zhang, Xizhi, Zhu, Caiyun, Gubat, Johannes Artiaga, Chen, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077961/
https://www.ncbi.nlm.nih.gov/pubmed/31917701
http://dx.doi.org/10.1097/CAD.0000000000000891
_version_ 1783507529540567040
author Liu, Min
Jia, Qingqing
Wang, Xiaolin
Sun, Changjiang
Yang, Jianqi
Chen, Yanliang
Li, Ying
Min, Lingfeng
Zhang, Xizhi
Zhu, Caiyun
Gubat, Johannes Artiaga
Chen, Yong
author_facet Liu, Min
Jia, Qingqing
Wang, Xiaolin
Sun, Changjiang
Yang, Jianqi
Chen, Yanliang
Li, Ying
Min, Lingfeng
Zhang, Xizhi
Zhu, Caiyun
Gubat, Johannes Artiaga
Chen, Yong
author_sort Liu, Min
collection PubMed
description Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2–6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and eight had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 and 221 days, respectively. There were five patients (13.15%) with grade 3/4 leukopenia, three patients (7.89%) with grade 3/4 neutropenia and one patient (2.63%) with grade 3/4 diarrhea. The combination of irinotecan plus raltitrexed was effective for pretreated ESCC patients. Further studies are needed to determine the optimal dose of the two drugs.
format Online
Article
Text
id pubmed-7077961
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-70779612020-03-25 Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer Liu, Min Jia, Qingqing Wang, Xiaolin Sun, Changjiang Yang, Jianqi Chen, Yanliang Li, Ying Min, Lingfeng Zhang, Xizhi Zhu, Caiyun Gubat, Johannes Artiaga Chen, Yong Anticancer Drugs Clinical Reports Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2–6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and eight had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 and 221 days, respectively. There were five patients (13.15%) with grade 3/4 leukopenia, three patients (7.89%) with grade 3/4 neutropenia and one patient (2.63%) with grade 3/4 diarrhea. The combination of irinotecan plus raltitrexed was effective for pretreated ESCC patients. Further studies are needed to determine the optimal dose of the two drugs. Lippincott Williams & Wilkins 2020-04 2020-03-13 /pmc/articles/PMC7077961/ /pubmed/31917701 http://dx.doi.org/10.1097/CAD.0000000000000891 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical Reports
Liu, Min
Jia, Qingqing
Wang, Xiaolin
Sun, Changjiang
Yang, Jianqi
Chen, Yanliang
Li, Ying
Min, Lingfeng
Zhang, Xizhi
Zhu, Caiyun
Gubat, Johannes Artiaga
Chen, Yong
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
title Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
title_full Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
title_fullStr Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
title_full_unstemmed Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
title_short Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
title_sort clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077961/
https://www.ncbi.nlm.nih.gov/pubmed/31917701
http://dx.doi.org/10.1097/CAD.0000000000000891
work_keys_str_mv AT liumin clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT jiaqingqing clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT wangxiaolin clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT sunchangjiang clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT yangjianqi clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT chenyanliang clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT liying clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT minlingfeng clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT zhangxizhi clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT zhucaiyun clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT gubatjohannesartiaga clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer
AT chenyong clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer